## Koichiro Kumagai

## List of Publications by Year in descending order

Source: https:/|exaly.com/author-pdf/3596316/publications.pdf
Version: 2024-02-01
36
papers
all docs

| 1 | JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2021, 85, 1104-1244. | 1.6 | 77 |
| :---: | :---: | :---: | :---: |
| 2 | JCS/JHRS 2019 guideline on nonâ€pharmacotherapy of cardiac arrhythmias. Journal of Arrhythmia, 2021, 37, 709-870. | 1.2 | 91 |
| 3 | Highâ€power, shortâ€duration ablation during Box isolation for atrial fibrillation. Journal of Arrhythmia, 2020, 36, 899-904. | 1.2 | 13 |
| 4 | Impact of Box Isolation on Rotors and Multiple Wavelets in Persistent Atrial Fibrillation. Circulation Journal, 2020, 84, 419-426. | 1.6 | 11 |
| 5 | Effects of additional ablation of lowâ€voltage areas after Box isolation for persistent atrial fibrillation. Journal of Arrhythmia, 2019, 35, 197-204. | 1.2 | 20 |
| 6 | What is the meaning of ageâ€related change in CFAE?. Journal of Arrhythmia, 2019, 35, 813-814. | 1.2 | 0 |
| 7 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018, 20, el-el60. | 1.7 | 767 |

8 Catheter Ablation of Posterior LA Isolation: Box Isolation. , 2018, , 169-174.
0
2017â€\%oHRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of
atrial fibrillation: Executive summary. Europace, 2018, 20, 157-208.
102017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of
$0.71,671$

| 11 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Journal of Arrhythmia, 2017, 33, 369-409. | 1.2 | 348 |
| :---: | :---: | :---: | :---: |
| 12 | 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 1-55. | 1.3 | 83 |

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of
atrial fibrillation: Executive summary. Heart Rhythm, 2017, 14, e445-e494. $0.7 \quad 135$ atrial fibrillation: Executive summary. Heart Rhythm, 2017, 14, e445-e494.

Usefulness of ablation of complex fractionated atrial electrograms using nifekalant in persistent atrial fibrillation. Journal of Cardiology, 2013, 61, 44-48.
1.9

18

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial
15 Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and
$0.71,541$
Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.
Hybrid therapy for refractory atrial fi brillation : combining catheter ablation and anti-arrhythmic drugs. Japanese Journal of Electrocardiology, 2012, 32, 205-207.

| 19 | Catheter Ablation of Atrial Fibrillation. Circulation Journal, 2011, 75, 2305-2311. | 1.6 |
| :---: | :---: | :---: |
| 20 | Long-Term Effects of Box Isolation on Sympathovagal Balance in Atrial Fibrillation. Circulation Journal, 2010, 74, 1096-1103. | 1.6 |
| 21 | Comparison of the Effects of Na <sup>+<\|sup> and K<sup>+<\|sup> Channel Blockers on the Electrophysiological Properties of the Pulmonary Veins in Patients with Atrial Fibrillation. Journal of Arrhythmia, 2010, 26, 259-266. | 1.2 |
| 22 | Does Atrialâ€Pacing from Different Intraâ€Atrial Sites for Atrial Fibrillation Effect Pulmonary Venous Pressure?. Journal of Arrhythmia, 2010, 26, 176-180. | 1.2 |
| 23 | Noncontact Mapping-Guided Catheter Ablation of Atrial Fibrillation. Circulation Journal, 2009, 73, 233-241. | 1.6 |

24 Upstream Therapy for Atrial Fibrillation. Circulation Journal, 2007, 71, A75-A81. ..... 1.65
25 Efficacy and Safety of Catheter Ablation for Persistent or Permanent Atrial Fibrillation. Journal of Arrhythmia, 2007, 23, 229-235.
27 Pilsicainide for Atrial Fibrillation. Drugs, 2006, 66, 2067-2073.Journal, 2005, 69, 1503-1507.

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial

